Combined treatment with amlodipine and atorvastatin calcium reduces circulating levels of intercellular adhesion molecule-1 and tumor necrosis factor-α in hypertensive patients with prediabetes

Frontiers in Aging Neuroscience

Volumn 8, Issue AUG, 2016, Pages

  Huang, Zhouqing ^a   Chen, Chen ^a   Li, Sheng ^a   Kong, Fanqi ^a   Shan, Peiren ^a   Huang, Weijian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Amlodipine and atorvastatin calcium; Endothelial dysfunction; Hypertension; Inflammation; Intercellular adhesion molecule 1; Prediabetes; Tumor necrosis factor

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIET RESTRICTION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE 1 BLOOD LEVEL; MALE; PILL; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 84990070018     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2016.00206     Document Type: Article

References (22)

1. American Diabetes Association. (2010). Standards of medical care in diabetes-2010. Diabetes Care 33, S11-S61. doi: 10.2337/dc10-s011
2. Ascer, E., Bertolami, M. C., Venturinelli, M. L., Buccheri, V., Souza, J., Nicolau, J. C., et al. (2004). Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177, 161-166. doi: 10.1016/j.atherosclerosis.2004.07.003
3. Chapman, M. J., and Sposito, A. C. (2008). Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol. Ther. 117, 354-373. doi: 10.1016/j.pharmthera.2007.10.004
4. Charbonneau, F., Anderson, T. J., Title, L., Jobin, J., Poirier, P., Huyhn, T., et al. (2008). Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197, 420-427. doi: 10.1016/j.atherosclerosis.2007.06.019
5. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., et al. (2003). Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 42, 1206-1252. doi: 10.1161/01.HYP.0000107251.49515.c2
6. Davignon, J. (2004). Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43. doi: 10.1161/01.cir.0000131517.20177.5a
7. Davignon, J., and Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis. Circulation 109, III27-III32. doi: 10.1161/01.CIR.0000131515.03336.f8
8. DeFronzo, R. A., and Abdul-Ghani, M. (2011). Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108, 3B-24B. doi: 10.1016/j.amjcard.2011.03.013
9. Ezzati, M., Vander Hoorn, S., Lawes, C. M., Leach, R., James, W. P., Lopez, A. D., et al. (2005). Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med. 2:e133. doi: 10.1371/journal.pmed.0020133
10. Fogari, R., Preti, P., Zoppi, A., Lazzari, P., Corradi, L., Fogari, E., et al. (2006). Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 62, 817-822. doi: 10.1007/s00228-006-0176-1
11. García-Puig, J., Ruilope, L. M., Luque, M., Fernández, J., Ortega, R., Dal-Ré, R., et al. (2006). Glucose metabolism in patients with essential hypertension. Am. J. Med. 119, 318-326. doi: 10.1016/j.amjmed.2005.09.010
12. Gu, P., Jiang, W., Cheng, M., Lu, B., Shao, J., Du, H., et al. (2012). Glucose metabolism in outpatients with new-onset hypertension in Chinese Han population. Clin. Exp. Hypertens. 34, 474-481. doi: 10.3109/10641963.2012.666601
13. Kawai, H., Deguchi, S., Deguchi, K., Yamashita, T., Ohta, Y., Shang, J., et al. (2011). Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res. 1368, 317-323. doi: 10.1016/j.brainres.2010.10.046
14. Landsberger, M., Wolff, B., Jantzen, F., Rosenstengel, C., Vogelgesang, D., Staudt, A., et al. (2007). Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 190, 43-52. doi: 10.1016/j.atherosclerosis.2006.02.009
15. Levitan, E. B., Song, Y., Ford, E. S., and Liu, S. (2004). Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch. Intern. Med. 164, 2147-2155. doi: 10.1001/archinte.164.19.2147
16. Libby, P. (2002). Inflammation in atherosclerosis. Nature 420, 868-874. doi: 10.1038/nature01323
17. Magen, E., Feldman, A., Cohen, Z., Alon, D. B., Minz, E., Chernyavsky, A., et al. (2010). Circulating endothelial progenitor cells, Th1/Th2/Th17-related cytokines and endothelial dysfunction in resistant hypertension. Am. J. Med. Sci. 339, 117-122. doi: 10.1097/maj.0b013e3181c6a968
18. Rosamond, W., Flegal, K., Friday, G., Furie, K., Go, A., Greenlund, K., et al. (2007). Heart disease and stroke statistics-2007 update: a report from the American Heart association statistics committee and stroke statistics subcommittee. Circulation 115, e69-e171. doi: 10.1161/CIRCULATIONAHA.106.179918
19. Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D., et al. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711-1718. doi: 10.1001/jama.285.13.1711
20. Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., et al. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158. doi: 10.1016/S0140-6736(03)12948-0
21. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano, A. L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M. R., et al. (2011). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217, S1-S44. doi: 10.1016/j.atherosclerosis.2011.06.012
22. Zhang, X., Tian, F., Kawai, H., Kurata, T., Deguchi, S., Deguchi, K., et al. (2012). Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats. Transl. Stroke Res. 3, 435-441. doi: 10.1007/s12975-012-0198-1